Skip to content

Lymphoma Follow-up

Lymphoma Follow-up Protocol

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00744120
Enrollment
51
Registered
2008-08-29
Start date
2003-10-31
Completion date
2013-09-30
Last updated
2013-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

cancer

Brief summary

This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.

Detailed description

The intent of this protocol is to accrue up to 800 volunteers who are interested in participating in NIA research studies as part of follow-up for previous cancer treatment at NIH. Participants will be asked to answer questions regarding their general health status, diagnoses, and admissions to hospital, and to provide possible documentation. They may be asked to come to the NIA Clinical Research Unit at Harbor Hospital to participate in a follow-up evaluation. They will have the opportunity to obtain additional information about studies in which they may wish to participate and to discuss eligibility issues with NIA staff members. Any identified clinical problems in need of care will also be discussed. Volunteers may be referred, with their permission, to their private medical doctor for follow-up. They may be re-evaluated within a year for further follow-up. The follow-up evaluation may include history and physical, blood and urine tests, questionnaire, MRI or CT.

Interventions

None listed

Sponsors

National Institute on Aging (NIA)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Previously treated on an approved NCI/NIH protocols * Willing and able to provide informed consent for current NIA protocol * Rare, unusual, interesting or unknown condition that requires diagnosis

Exclusion criteria

* Does not meet the criteria of any previously-approved NIH Protocol.

Design outcomes

Primary

MeasureTime frame
Long-term survival following treatment for lymphomaAnnually

Secondary

MeasureTime frame
Long-term toxicity possibly attributable to lymphoma or treatment for lymphomaAnnually

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026